Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us

Registration           Hotel           Late Breaking Abstract Submission     Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
Poster Session OT1
Poster Session OT2
Poster Session OT3
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6

Program Schedule   >  Poster Sessions - Poster Session 2

Poster Session 2 
  Detection and Diagnosis: Breast Imaging - Mammography
P2-01-01 Impact of California breast density notification law SB 1538 on California women and their health care providers
Ikeda DM, Thomas WR, Joe BN, Lindfors K, Brenner RJ, Feig S, Bassett LW, Leung JW, Ojeda-Fournier H, Hargreaves J, Price E, Lipson J, Kurian AW, Love E, Walgenbach DD, Ryan L, Durbin M, Daniel BL, Nayak L, Sickles EA. Stanford University, Stanford, CA; University of California San Francisco, San Francisco, CA; University of California Davis, Davis, CA; Alta Bates – Summit Medical Center, Berkeley, CA; University of California Irvine, Irvine, CA; University of California Los Angeles, Los Angeles, CA; California Pacific Medical Center, San Francisco, CA; University of California San Diego, San Diego, CA; Palo Alto Medical Foundation, Palo Alto, CA.
P2-01-02 Withdrawn
P2-01-03 Withdrawn
P2-01-04 High-density lipoprotein cholesterol is associated with mammographic density in premenopausal women
Flote VG, Frydenberg H, Ursin G, Wilsgaard T, Iversen A, Ellison PT, Wist EA, Egeland T, Thune I, Furberg A-S. The Cancer Center, Oslo University Hospital, Oslo, Norway; The Cancer Registry of Norway, Oslo, Norway; Faculty of Health Sciences, University of Tromsø, Tromsø, Norway; Harvard University, Cambridge, MA; Norwegian University of Life Sciences, Aas, Norway.
P2-01-05 Mammographic microcalcifications and breast cancer tumorigenesis: A radiologic-pathologic analysis
Naseem M, Murray J, Hilton JF, Manoharan AS, Polenz CK, Han D, Hogeveen S, Heersink RL, Bookwala A, Muradali D, Karamchandani J, Bell D, Brezden-Masley CB. St. Michael's Hospital, Toronto, ON, Canada.
P2-01-06 How much agreement can we expect on BI-RADS mammographic findings? Observer agreement among 10 expert mammographers
Wisner DJ, Feig S, Joe B, Hargreaves J, Ojeda-Fournier H, Bassett L, Aminololama-Shakeri S, DeGuzman JQ, Flowers CI, Campbell JE, Elson S, Retallack H, Wells C. University of California, San Francisco, San Francisco, CA; University of California, Irvine, Irvine, CA; University of California, Davis, Davis, CA; University of California, San Diego, San Diego, CA; University of California, Los Angeles, Los Angeles, CA; Cancer Imaging Advisors, Tampa, FL.
P2-01-07 Analysis of the relationship between breast cancer risk-related gene polymorphisms, ESR1/6q25.1-rs2046210 and mammographic breast density
Nogami T, Taira N, Mizoo T, Nishiyama K, Iwamoto T, Motoki T, Shien T, Matsuoka J, Doihara H, Ishihara S, Kawai H, Kawasaki K, Ogasawara Y, Ishibe Y. Okayama University Hospital, Okayama, Japan; Okayama Saiseikai General Hospital, Okayama, Japan; Okayama Rosai Hospital, Okayama, Japan; Kagawa Prefectural Central Hospital, Breast Surgery, Takamatsu, Kagawa, Japan; Mizushima Kyodo Hospital, Breast Surgery, Kurashiki, Okayama, Japan.
P2-01-08 Imaging overview of metaplastic carcinomas of the breast; a study of 46 cases
Langlands FE, Dall B, Dodwell D, Shabaan AM, Sharma N. St James University Hospital NHS Trust, Leeds, West-Yorkshire, United Kingdom.
  Detection and Diagnosis: Breast Imaging - MRI
P2-02-01 Did established clinical practice regarding MRI bias the COMICE trial?
McMahon MA, Sharma N, Shaaban A, Dall BJG. The Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom.
P2-02-02 Cancer detection rate in high-risk patients on short-term, and long-term follow-up MRI after a benign concordant MRI-guided breast biopsy
Den EI, Laguna BA, Weinstein SP, Roth SG. Hospital of the University of Pennsylvania, Philadelphia, PA. Elana Ida Den is a recipient of an SABCS Clinical Scholars scholarship
P2-02-03 Multiparametric MR imaging of the breast with dynamic contrast-enhanced MR imaging, diffusion-weighted imaging and proton MR spectroscopy: Are all three parameters necessary for accurate breast cancer diagnosis?
Pinker-Domenig K, Bogner W, Gruber S, Dubsky PC, Bago-Horvath Z, Bartsch R, Helbich T. Medical University of Vienna, Vienna, Austria.
P2-02-04 Kinetic heterogeneity features on breast DCE-MRI as prognostic markers of breast cancer recurrence
Mahrooghy M, Ashraf AB, Gavenonis SC, Daye D, Mies C, Feldman M, Rosen M, Kontos D. University of Pennsylvania, Philadelphia, PA; Christiana Care Health System, Newark, DE.
P2-02-05 Withdrawn
P2-02-06 Breast cancer in the elderly: Is MRI helpful?
Pilewskie M, Hirsch A, Eaton AA, Stempel M, Morris E, Gemignani ML. Memorial Sloan-Kettering Cancer Center, New York, NY.
P2-02-07 Preoperative breast MRI and follow-up recommendations for the contralateral breast influence the rate of contralateral prophylactic mastectomy
Xia C, Button AM, Smith BJ, Grobe CC, Schroeder MC, Sugg S, Weigel RJ, Thomas A. University of Iowa, Iowa City, IA.
P2-02-08 MRI in predicting pathological response of breast cancer after neoadjuvant chemotherapy: Correlation with tumor size and morphology changes
Woo O, Seo JH, Yang DS, Kim WY. Korea University Guro Hospital, Seoul, Republic of Korea.
P2-02-09 Accuracy of MRI for estimating residual tumor size after neoadjuvant endocrine therapy in early stage breast cancer with ER positive and HER2 negative
Nakamura R, Yamamoto N, Yoshii A, Itami M. Chiba Cancer Center Hospital Division of Breast Surgery, Chiba, Japan; Chiba Cancer Center Hospital Division of Diagnostic Pathology, Chiba.
P2-02-10 Evaluation of apparent diffusion coefficient to predict grade, micro-invasion and invasion in DCIS
Hussein HM, Chung C, Moshonov H, Freitas V, Miller N, Kulkarni SR, Scaranelo A. University of Toronto, Toronto, ON, Canada.
P2-02-11 Accuracy of MRI and ultrasonography in predicting pathologic complete response in breast cancer patients treated with neoadjuvant chemotherapy
Hayashi N, Tsunoda H, Matsuda N, Nakamura S, Tsugawa K, Akiyama F, Takahashi Y, Yoshida A, Yagata H, Suzuki K, Yamauchi H. St. Luke's International Hospital, Tokyo, Japan; The Showa University School of Medicine, Tokyo, Japan; St. Marianna University School of Medicine, Tokyo, Japan; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
P2-02-12 Computer derived image features on DCE-MRI appear to distinguish estrogen receptor-positive breast cancers with low and high oncotype DX recurrence scores
Madabhushi A, Wan T, Bloch B, Plecha D, Thompson C, Gilmore H, Avril N, Jaffe C, Harris L. Case Western Reserve University, Cleveland, OH; Boston University School of Medicine, Boston, MA; UH MacDonald Women's Hospital Breast Centers, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; Seidman Cancer Center, Cleveland, OH.
P2-02-13 The clinical significance of breast MRI in the management of ductal carcinoma in situ diagnosed on needle biopsy
Miyashita M, Ishida T, Amano G, Tamaki K, Ohuchi N. Tohoku University; Nihonkai General Hospital.
P2-02-14 A novel approach to screening breast MRI: MIP and FAST breast MRI
Kuhl CK, Schrading S, Strobel K, Schild H, Bieling HB. University of Aachen, RWTH, Aachen, Germany; University of Bonn, Bonn, Germany.
  Detection and Diagnosis: Breast Imaging - Other
P2-03-01 Computer extracted image texture features on T2-weighted MRI appear to correlate with nuclear morphologic descriptors from H&E-stained histopathology in estrogen receptor positive breast cancers
Madabhushi A, Basavanhally AN, Doyle S, Wan T, Singanamalli A, Thompson C, Gilmore H, Plecha D, Harris L. Case Western Reserve University, Cleveland, OH; Rutgers, The State University of New Jersey, Piscataway, NJ; Ibris, Inc., Monmouth Junction, NJ.
P2-03-02 A non-invasive modality the US virtual touch tissue quantification (VTTQ) for evaluation of breast cancer
Tamaki K, Tamaki N, Kamada Y, Uehara K, Sasano H, Miyashita M, Ishida T, Ohuchi N. Nahanishi Clinic Okinawa, Naha, Okinawa, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
P2-03-03 Feasibility of evaluation of breast tissue using confocal microscopy with strip mosaicing
Abeytunge S, Larson B, Rajadhayksha M, Morrow M, Murray M. Memorial Sloan-Kettering Cancer Center, New York, NY.
P2-03-04 Withdrawn
P2-03-05 Relationship between 64Cu-DOTA-trastuzumab positron emission tomography uptake and assessment of HER2 by immunohistochemistry in women with advanced breast cancer
Mortimer JE, Colcher D, Frankel P, Raubitschek A, Carroll M, Conti P, Tong S, Poku K, Miles J, Bading J. City of Hope/Beckman Research Institute, Duarte; University of Southern California.
P2-03-06 Sonographic evaluation of MRI-detected lesions of the breast using image fusion technique with magnetic navigation
Nakano S, Fujii K, Yoshida M, Fukutomi T, Ishiguchi T. Aichi Medical University, Nagakute, Aichi, Japan.
P2-03-07 Prediction of the pathological response to neoadjuvant chemotherapy in patients with breast cancer using sonazoid-enhanced ultrasonography
Amioka A, Masumoto N, Kajitani K, Emi A, Shigematsu H, Kadoya T, Haruta R, Kataoka T, Arihiro K, Okada M. Department of Surgical Oncology, Hiroshima-shi, Hiroshima-ken, Japan; Department of Breast Surgery, Hiroshima-shi, Hiroshima-ken, Japan; Department of Anatomical Pathology, Hiroshima-shi, Hiroshima-ken, Japan.
P2-03-08 Usefulness of sonazoid-enhanced ultrasonography in the evaluation of the biological features of breast cancer
Masumoto N, Amioka A, Kajitani K, Emi A, Shigematsu H, Kadoya T, Haruta R, Kataoka T, Okada M. Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; Hiroshima University Hospital, Hiroshima, Japan.
P2-03-09 Tissue hemoglobin oxygen saturation measured by photoacoustic mammography correlates with microvasculature properties assessed by histological image analysis, a preliminary study
Fakhrejahani E, Torii M, Yamaga I, Asao Y, Kitai T, Kataoka M, Kanao S, Takada M, Shiina T, Toi M. Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan.
P2-03-10 Non-invasively measured Warburg effect: Optically measured tissue oxygenation and its correlation with Ki67 proliferation
Chung SH, Feldman MD, Martinez D, Kim H, Busch DR, Yodh AG. University of Pennsylvania; Hospital of the University of Pennsylvania; The Children's Hospital of Philadelphia; University of Rochester.
P2-03-11 In situ imaging of the tumor cavity during breast lumpectomy using optical coherence tomography
Boppart SA, Nolan RM, Erickson-Bhatt SJ, Shemonski ND, Adie SG, Putney J, Darga D, McCormick DT, Cittadine A, Marjanovic M, Zysk AM, Chaney EJ, Monroy GL, South FA, Carney PS, Cradock KA, Liu ZG, Ray PS. University of Illinois Urbana-Champaign, Urbana, IL; Diagnostic Photonics Inc, Champaign, IL; AdvancedMEMS, San Francisco, CA; Carle Foundation Hospital, Urbana, IL; University of Illinois College of Medicine and Carle Cancer Center, Urbana, IL.
  Detection and Diagnosis: Screening
P2-04-01 Decreased need for adjuvant chemotherapy treatment related to mammography detection of breast cancer in women age 65-74
Kaplan HG, Malmgren JA, Atwood MK. Swedish Cancer Institute, Seattle, WA; HealthStat Consulting, Inc, Seattle, WA.
P2-04-02 Overdiagnosis in mammography screening in two randomised trials in Malmö, Sweden – An age specific analysis
Jonsson H, Johansson R, Andersson I, Zackrisson S. Umeå University, Umeå, Sweden; Lund University, Malmö, Sweden.
P2-04-03 Can the interval cancer ratio diminish the need for background incidence estimates as a mammography screening programme performance indicator?
Andersen SB, Euler-Chelpin MV, Lynge E, Törnberg S, Njor SH. University of Copenhagen, Copenhagen, Denmark; Karolinska Instituttet, Stockholm, Sweden.
P2-04-04 Breast cancer risk reduction in high risk women identified at the time of screening mammography. Integrating data from an established high risk clinic
Lopresti ML, Edmiston KL, Oconnor A, Gates E, Vijayaraghavan G, Sood R, Khanna S. Umass Memorial Medical Center, Worcester, MA.
P2-04-05 Pros and cons of breast cancer screening: Knowledge in lay women
Morère J-F, Pivot X, Touboul C, Viguier J, Blay J-Y, Coscas Y, Lhomel C, Eisinger F. Hôpital Paul Brousse, Villejuif, France; Hopital Jean Minjoz, Besançon, France; KantarHealth, Montrouge, France; CHRU Trousseau, Tours, France; Centre Léon Berard, Lyon, France; Clinique de la Porte de Saint Cloud, Boulogne Billancourt, France; Roche SAS, Boulogne Billancourt, France; Institut Paoli Calmettes, Marseille, France.
P2-04-06 Successful results of a population-based organized mammography screening program in a developing country: The Turkish experience
Ozmen V, Ozkan-Gurdal S, Kayhan A, Ozaydin N, Cabioglu N, Ozcinar B, Aribal E. Istanbul University, Faculty of Medicine, Istanbul, Turkey; Faculty of Medicine, Namik Kemal University, Tekirdag, Turkey; Marmara University, Istanbul, Turkey; Faculty of Medicine, Acibadem University, Istanbul, Turkey; Faculty of Medicine, Marmara University, Istanbul, Turkey.
P2-04-07 Insurance status as predictor of repeat mobile mammography utilization: 10 year analysis of a comprehensive cancer center
Riley EC, Roland LM, Barkley LE, Mandadi M, Pan J, Rai SN, Mizuguchi SG. James Graham Brown Cancer Center/University of Louisville, Louisville, KY.
  Tumor Cell and Molecular Biology: Animal Models
P2-05-01 Induction of PELP1 expression in mammary gland promotes tumorigenesis by enhancing CDK-CyclinD1 signaling
Vadlamudi RK, Cortez VA, Zamora A, Martinez L, Tekmal RR. UT Health Sciences Center, San Antonio, TX.
P2-05-02 Prevention of murine mammary carcinogenesis by UVR-produced vitamin D3
Makarova AM, Davari P, Wang L, Wang G, Wang J, Epstein EH. Children's Hospital Oakland Research Institute, Oakland, CA.
P2-05-03 Role of tumor immune environment in tumor initiation and growth rates in mouse mammary tumor models
Stanton S, Gadd E, Rastetter L, Slota M, Koehnlein M, Treuting P, Disis M. University of Washington, Seattle, WA.
P2-05-04 Comparative expression profiling of patient samples and preclinical models of inflammatory breast cancer reveals gene signatures of epithelial plasticity and suppression of TGFb signaling
Van Laere SJ, Marsan M, Vermeulen PB, Viens P, Barsky SH, Cristofanilli M, Dirix LY, Bertucci F, Robertson FM. Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium.
P2-05-05 Canine invasive mammary carcinoma as a spontaneous model for insulin-like growth factor-1 receptor-overexpressing triple negative breast cancer
Jaillardon L, Nguyen F, Loussouarn D, Godard T, Abadie J, Siliart B, Campone M. LUNAM Université Oniris, AMaROC - LDHvet, Nantes, France; Hôpital G&R Laënnec, Saint Herblain, France; Institut de Cancérologie de l'Ouest, Saint Herblain-Nantes Cedex, France.
P2-05-06 Does the lipid mediator sphingosine-1-phosphate have a role in obesity-related cancer progression?
Nagahashi M, Yamada A, Aoyagi T, Huang W-C, Allegood JC, Milstien S, Spiegel S, Takabe K. Virginia Commonwealth University, Richmond, VA.
P2-05-07 Resveratrol blocks the protumorigenic effects of obesity in a postmenopausal breast cancer model
Rossi EL, Ford NA, Pruski M, Lashinger L, Hursting SD. University of Texas at Austin, Austin, TX.
P2-05-08 Combined neoadjuvant iniparib and carboplatin in locally advanced or metastatic canine mammary tumors (MT) to support human clinical studies
Morio F, Becavin S, Gogny A, Nguyen F, Albaric O, Labrut S, Séveno C, Vrignaud P, Juin P, Campone M, Abadie J, Ibisch C. LUNAM University, AMaROC Research Unit, Oniris, Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering, Nantes Cedex 3, France; Translational and Experimental Medicine, Sanofi Oncology, Vitry-sur-Seine, France; INSERM, Institut de Recherche Thérapeutique de l'Université de Nantes, Nantes Cedex 1, France; Integrated Center for Oncology ICO, Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint Herblain, France.
  Tumor Cell and Molecular Biology: Epigenetics
P2-06-01 cMethDNA is a quantitative circulating methylated DNA assay for detection of metastatic breast cancer and for monitoring response to therapy
Fackler MJ, Bujanda ZL, Umbricht C, Teo WW, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope LA, Wolff AC, Sukumar S. Johns Hopkins University School of Medicine, Baltimore, MD; Memorial Sloan-Kettering Cancer Center, NY, NY; Mayo Clinic, Rochester, MN; University of Pittsburgh Medical Center, Pittsburgh, PA; University of North Carolina, Chapel Hill, NC.
P2-06-02 Pparγ deacetylation by SIRT1 determines breast tumor lipid synthesis and growth
Pestell RG, Tian L, Wang C, Soccio R, Hagen FK, Chen ER, Gormley M, Zhong Z, Ertel A, Addya S, Zhou J, Powell MJ, Xu P, Casimiro MC, Lisanti MP, Fortina P, Deng H, Sauve AA. Thomas Jefferson University, Philadelphia, PA; University of Rochester, Rochester, NY; University of Pennsylvania, Philadelphia, PA; Weill Medical College of Cornell University, New York, NY; Rockefeller University, New York, NY.
P2-06-03 The BRCA1 promoter methylation is one of the mechanisms of th BRCA1 dysfunction of triple-negative breast cancer
Yamashita N, Tokunaga E, Tanaka K, Saeki H, Oki E, Kitao H, Morita M, Maehara Y. Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
P2-06-04 p300 acts as a tumor suppressor by inhibiting pro-metastatic microRNA pathways
Birnbaum M, Yuan H, Yue K, Bishopric NH. University of Miami, Miami, FL.
P2-06-05 Association of promoter methylation status of the FHIT gene and Fhit expression with HER2/neu status in breast cancer
Jeong YJ, Jang JI, Kim MS, Bong JG, Park SH, Oh HK. College of Medicine, Catholic University of Daegu, Daegu, Korea.
P2-06-06 ALU and LINE-1 hypomethylation is associated with HER2+/ER- subtype of breast cancer
Jung HY, Park SY, Jung N, Cho N-Y, Kang GH. Seoul National University Bundang Hospital, Seongnam, Gyoenggido, Korea; Seoul National University College of Medicine, Seoul, Korea; Laboratory of Epigenetics, Cancer Research Institute, Seoul National University, Seoul, Korea.
  Tumor Cell and Molecular Biology: Genetics - Germline
P2-07-01 Polymorphism A247S of XRCC4 contributes to the risk of breast cancer and impairs DNA damage repair pathway
He M, Hu X, Cao A-Y, Yu K-D, Shao Z-M, Di G-H. Fudan University Shanghai Cancer Center, Shanghai, China. Min He is a recipient of an Avon-AACR International Scholar-In-Training Award
P2-07-02 A novel megadeletion mouse model for mechanistic studies on the 8q24 non-coding breast cancer susceptibility locus
Smits BMG, Gould MN. Medical University of South Carolina, Charleston, SC; University of Wisconsin-Madison, Madison, WI.
P2-07-03 High-throughput germline mutation screening for hereditary breast cancer in southern Chinese patients by massively parallel DNA sequencing
Kwong A, Au CH, Law FB, Ho DN, Ip BK, Wong AT, Shin VY, Chan TL, Ma ES. The University of Hong Kong; Hong Kong Sanatorium & Hospital; Hong Kong Hereditary Breast Cancer Family Registry.
P2-07-04 HER2 overexpressing breast cancers are more frequent in carriers of TP53 DNA-binding domain mutations than in carriers of oligomerization-site mutations
Fitarelli-Kiehl M, Giacomazzi J, Santos-Silva P, Ashton-Prolla P. Genomic Medicine Laboratory, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Post-Graduate Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Post-Graduate Program in Medicine: Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
P2-07-05 Prevalence of germline BRCA1 and BRCA2 mutations in triple-negative breast cancer patients unselected for family history
Scott RJ, Wong-Brown M, Meldrum CJ, Avery-Kiejda K. University of Newcastle, Newcastle, New South Wales, Australia; Hunter Area Pathology Service, Newcastle, New South Wales, Australia.
P2-07-06 Detection of germline mutations in 196 genes in Chinese breast cancer families using targeted capture and next-generation sequencing
Yang X-C, Wu J, Lu J-S, Liu G-Y, Di G-H, Chen C-M, Hou Y-F, Huang X-Y, Liu Z-B, Yan X, Han Q-X, Shen Z-Z, Shao Z-M, Hu Z. Fudan University Shanghai Cancer Center, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China.
P2-07-07 Role of BRCA1 gene and its mutations in the development of family and early forms of breast cancer
Tukhtaboeva M, Abdulla A, Kamola G-A, Shahlo T. Tashkent Regional Oncology Dispensary, Tashkent, Uzbekistan; Tashkent City Oncology Dispensary, Tashkent, Uzbekistan; High Technologies Center, Tashkent, Uzbekistan.
  Tumor Cell and Molecular Biology: Genetics - Somatic
P2-08-01 Analysis of PIK3CA mutation abundance in primary breast cancer with droplet digital PCR identifies frequent sub-clonal PIK3CA mutations in ER negative and / or HER2 positive breast cancer
Garcia-Murillas I, Pearson A, Lambros M, Natrajan R, Segal C, Dowsett M, Turner NC. Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom.
P2-08-02 Chronic inflammation and the development of breast cancer
Clare SE, Pardo I, Lillemoe HA, Blosser R, Sauder CAM, Doxey DK, Badve S, Atale R, Radovich M, Choi M. Northwestern University Medical School, Chicago, IL; Indiana University School of Medicine, Indianapolis, IN.
P2-08-03 Patterns of somatic mutations in metaplastic carcinoma of the breast
O'Toole SA, Yu B, Ng CC, Selinger CI, Cooper WA, Carmalt H, Mak C, Chan C, Lee S, Karim R, Beith J, Cooper C. Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia; Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Western Sydney, Campbelltown, NSW, Australia; Concord Repatriation General Hospital, Concord, NSW, Australia; Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
P2-08-04 Subtype specific chromosomal aberrations in breast cancer
Tokunaga E, Yamashita N, Tanaka K, Saeki H, Oki E, Kitao H, Morita M, Maehara Y. Kyushu University, Fukuoka, Japan.
P2-08-05 Functional characterization of three novel breast cancer-related somatic mutations in metalloproteinase-disintegrin ADAM12
Qi Y, Duhachek-Muggy S, Li H, Zolkiewska A. Kansas State University, Manhattan, KS.
  Tumor Cell and Molecular Biology: New Drugs and Mechanisms
P2-09-01 Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer
Lindeman GJ, Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE. The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; The Royal Melbourne Hospital, Parkville, VIC, Australia; The University of Melbourne, Parkville, VIC, Australia; The Royal Women's Hospital, Parkville, VIC, Australia.
P2-09-02 BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations
Mina LA, Ramanathan RK, Wainberg ZA, Byers LA, Chugh R, Sachdev JC, Matei D, Zhang C, Henshaw JW, Dorr A, Kaye SB, de Bono JS. Indiana University, Indianapolis, IN; Virginia G. Piper Cancer Center @ Scottsdale Healthcare/TGen, Scottsdale, AZ; David Geffen School of Medicine at University of California, Los Angeles, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; BioMarin Pharmaceutical Inc, San Rafael, CA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.
P2-09-03 Antitumor activity of the glutaminase inhibitor, CB-839, in triple-negative breast cancer
Gross M, Budczies J, Demo S, Janes J, Lewis E, Parlati F, MacKinnon A, Rodriguez M, Yang J, Zhao F, Richardson A, Denkert C, Fiehn O, Bennett M. Calithera Biosciences, South San Francisco, CA; Sanford-Burnham Medical Research Institute, La Jolla, CA; Institut für Pathologie, Charité - Universitätsmedizin Berlin, Berlin, Germany; University of California Davis, Davis, CA.
P2-09-04 Development of novel combination therapy of IGF-1R/InsR and MEK inhibitors in triple-negative breast cancer (TNBC)
Kai K, Kondo K, Bartholomeusz C, Valero V, Hortobagyi GN, Ueno NT. The University of Texas MD Anderson Cancer Center, Houston, TX.
P2-09-05 The potent anti-androgen enzalutamide demonstrates broad anti-tumour activity across all androgen receptor-positive triple-negative breast cancer subtypes
Denne L, Shia A, Komulainen E, Haley V, Lenihan C, Cavicchioli F, O'Leary K, Schmid P. Barts/Brighton Experimental Cancer Medicine Centre, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.
P2-09-06 The role of p53 family tumor suppressors in mediating response to aurora kinase inhibition in triple-negative breast cancer
Diamond JR, Tan AC, Ionkina AA, Newton TP, Pitts TM, Eckhardt SG, Tentler JJ. University of Colorado Cancer Center, Aurora, CO.
P2-09-07 Inhibition of aurora-A by MLN8237 decreases SMAD5 expression and increases effectiveness of chemotherapeutic agents in breast cancer cells
Opyrchal M, Iankov I, Ingle JN, Galanis E, D'Assoro AB. Mayo Clinic College of Medicine, Rochester, MN.
P2-09-08 Therapeutic potential of the dual HER1/2 inhibitor AZD8931 in circumventing endocrine resistance
Morrison GD, Fu X, Shea M, Mitchell T, Giuliano M, Osborne C, Klinowska T, Rimawi MF, Schiff R. Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom.
P2-09-09 Withdrawn
P2-09-10 Antiprogestin CDB4124 suppressed progesterone receptor-mediated DNA binding activity, proliferation and gene expression in T47D cancer cells and normal human breast microstructures
Gupta A, Ivancic D, Wang J, Horvath E, Lee O, Whiele R, Khan SA. Northwestern University, Chicago, IL; Repros Therapeutics Inc, The Woodlands, TX.
P2-09-11 Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small molecule library
Fujita T, Mizukami T, Okawara T, Inoue K, Fujimori M. Tokyo Medical University Ibaraki Medical Center, Ami Inashiki, Ibaraki, Japan; Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, Japan; Kumamoto Health Science University, Kumamoto, Japan; Pharma Valley Center, Shizuoka Industrial Foundation, Nagaizumi Sunto, Shizuoka, Japan.
P2-09-12 Withaferin A-mediated inhibition of breast carcinoma involves concomitant activation of CHOP and Elk1 via ERK/ribosomal S6 kinase (RSK) signaling axis regulating death receptor 5 expression
Sharma D, Nagalingam A, Kuppusamy P, Saxena N. Johns Hopkins University, Baltimore, MD; University of Maryland, Baltimore, MD.
P2-09-13 Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway
Li T, Hu X, Zhang Q, Zhang J. Fudan University Shanghai Cancer Center, Shanghai, China.
P2-09-14 Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target breast cancer stem cells
Pachter JA, Kolev VN, Wright QG, Vidal CM, Pavdal MV, Ring JE, Shapiro IM, Weaver DT, Keegan M, Horobin JC, Xu Q. Verastem, Inc., Cambridge, MA.
P2-09-15 Effect of [4-valine 5-glutamine] desmopressin, a novel vasopressin analog, on human breast cancer cell growth in two-dimensional (2D) and three-dimensional (3D) cultures
Garona J, Pifano M, Pastrian B, Iannucci N, Gomez DE, Alonso DF, Ripoll GV. Laboratory of Molecular Oncology, Quilmes National University, Bernal, Buenos Aires, Argentina; Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Ciudad de Buenos Aires, Buenos Aires, Argentina.
P2-09-16 Pre-clinical evaluation of novel anti-angiogenic agents as breast cancer therapeutics
McGarrigle SA, Murphy A, Kennedy BN, Reynolds A, O'Sullivan JN, Kennedy MJ, Connolly EM. Trinity College Dublin and St. James's Hospital, Dublin, Ireland; Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland; Academic Unit of Clinical and Medical Oncology, Trinity College Dublin and St. James's Hospital, Dublin, Ireland.
P2-09-17 Allosteric inhibitors of the proteasome: A new concept for breast cancer treatment
Osmulski PA, Gaczynska M. University of Texas Health Science Center at San Antonio, San Antonio, TX.
P2-09-18 Identification of synergistic drug combination for HER2 positive breast cancer
Chalugun P, Shim JS, Liu JO. Johns Hopkins School of Medicine, Baltimore, MD.
P2-09-19 Zerumbone suppresses IL-1β-induced cell migration and invasion through inhibition of IL-8 expression and MMP3 expression in human triple negative breast cancer cells
Bae SY, Han JH, Kim S, Lee SK, Lee JH, Lee HC, Kim M, Kim J, Kil WH, Kim SW, Lee JE, Nam SJ. Samsung Medical Center, Sungkyunkwan University School of Medicine.
P2-09-20 2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate (BzATP) is a potential drug for triple negative breast cancer: Autophagy and apoptosis inducer
Lertsuwan J, Sikes RA. University of Delaware, Newark, DE.
P2-09-21 Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple-negative breast cancer (TNBC) cells via modulation of multiple cell signal pathways
Jiang M, Huang O, Xie Z, Shen K. The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; Comprehensive Breast Health Centre, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
P2-09-22 Synthesis of nitroxyl radical-containing nanoparticles with pH-sensitive behavior and their application for cancer therapy
Yu A, Wang H, Zhang T, Wang Y. Central Laboratory, College of Chemistry, Nankai University, Tianjin, China; Key Laboratory of Bioactive Materials (Ministry of Education), College of Life Sciences, Nankai University, Tianjin, China; Synergetic Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin, China.
  Prognosis and Response Prediction: Prognostic Factors and Biomarkers - Preclinical
P2-10-01 Withdrawn
P2-10-02 PD-L1 protein expression is a prognostic biomarker in breast cancer
Wimberly H, Schalper K, Chen L, Velcheti V, Pusztai L, Rimm D. Yale University School of Medicine, New Haven, CT.
P2-10-03 Metastasis-associated in colon cancer 1 predicts poor outcomes in patients with breast cancer
Lee JS, Cho JS, Park MH, Yoon JH. Chonnam National University Medical School, Gwangju, Republic of Korea.
P2-10-04 The clinicopathological features of androgen receptor expression in primary HER2-positive breast carcinomas
Yamashita T, Aruga T, Miyamoto H, Kitagawa D, Idera N, Goto R, Horiguchi K, Kuroi K. Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
P2-10-05 Lymphatic and pro-inflammatory candidate gene variations and breast-cancer related lymphedema
Fu MR, Axelrod D, Guth AA, Goldberg J, Li X, Cartwright F, Haber J, Conley Y. New York University, New York, NY; NYU School of Medicine, New York, NY; University of Pittsburgh, Pittsburgh, PA; NYU Cancer Center, New York, NY.
P2-10-06 Serum protein peak 3144m/z is a potential prognostic factor for postmenopausal breast cancer patients
Gao Y, Wang X-J, Xu S-H, Yang H-J, Chen Z-H, Cao W-M. Zhejiang Cancer Research Institute, Hangzhou, Zhejiang, China; Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
P2-10-07 Ep-ICD overexpression associates with poor prognosis in invasive ductal carcinoma
Matta A, ASSI J, Srivastava G, Chang MC, Ralhan R, Walfish PG. Mount Sinai Hospital, Toronto, ON, Canada.
P2-10-08 Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse
Yu K-D, Shao Z-M. Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
  Prognosis and Response Prediction: Prognostic Factors and Biomarkers - Clinical
P2-11-01 Withdrawn
P2-11-02 Understanding the biology and prognosis of PIK3CA gene mutations in primary breast cancer using gene expression profiling: A pooled analysis
Zardavas D, Fumagalli D, Borwn DN, Desmedt C, Metzger-Filho O, Piccart M, Sotiriou C, Michieles S, Loi S. Institut Jules Bordet, Brussels, Belgium; Breast Cancer Translational Research Laboratory – J.C. Heuson, Institut Jules Bordet, Brussels, Belgium; Dana-Farber Cancer Institute, Boston; Gustave Roussy, Paris-Sud University, Villejuif, France; Peter MacCallum Cancer Centre, Melbourne, Australia. Dimitrios Zardavas is a recipient of an SABCS Clinical Scholars scholarship
P2-11-03 A tumor microenvironment of metastasis (TMEM) biomarker in early breast cancer provides prognostic information that is complementary to IHC4: A prospective validation study
Sparano JA, Rohan TE, Xue X, Lin H-M, D'Alfonso TM, Ginter PS, Oktay MH, Robinson BD, Ginsberg M, Gertler FB, Glass AG, Condeelis JS, Jones JG. Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center, Bronx, NY; Mount Sinai School of Medicine, New York, NY; Weill Cornell Medical College, New York, NY; Massachusetts Institute of Technology, Boston, MA; Kaiser Permanente Northwest, Portland, OR.
P2-11-04 Expression of immune checkpoint related genes are prognostic in untreated breast cancer
Bianchini G, Rossi CM, Iwamoto T, Karn T, Callari M, Kelly CM, Pusztai L, Gianni L. San Raffaele Scientific Institute, Milan, Italy; University Graduate School of Medicine and Dentistry, Okayama, Japan; J.W. Goethe University, Frankfurt, Germany; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Mater Misericordiae University Hospital, Dublin, Ireland; Yale Cancer Center, New Haven.
P2-11-05 Withdrawn
P2-11-06 Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy – A GEICAM/ 9906 sub-study
Martin M, Brase JC, Perou CM, Ruiz A, Prat A, Weber KE, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Kronenwett R, Santaballa AM, Rodriguez CA, Alvarez IM, Segui MA, Casas M, Carrasco E, Caballero R, Rodriguez-Lescure A. Instituto de Investigación Sanitaria Gregorio Marañon. Universidad Complutense, Madrid, Spain; Sividon Diagnostics GmbH, Cologne, Germany; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Vall d´Hebron Institute of Oncology, Barcelona, Spain; Complexo Hospitalario Universitario A Coruña, A Coruña, Spain; University of Utah Health Sciences Center/Huntsman Cancer Institute, Salt Lake City, UT; Hospital Universitario Virgen del Rocio, Sevilla, Spain; Hospital Universitario La Fe, Valencia, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Corporación Sanitaria Parc Taulí, Sabadell, Spain; Spanish Breast Cancer Research Group, Madrid, Spain; Hospital General Universitario de Elche, Elche, Spain.
P2-11-07 Proteins predictive of bone metastasis development in breast cancer patients
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE. Leeds Institute of Cancer and Pathology, St. James's University Hospital, University of Leeds, Leeds, United Kingdom; Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, United Kingdom; Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom.
P2-11-08 IHC 2+ FISH (-) breast cancer (BC): Patient characteristics and outcomes: A comparison to HER2 IHC 0, 1+ and HER2 + BC diagnosed 2000-2006
Fehrenbacher L, Capra A, Fulton R, Habel L. Kaiser Permanente Northern California, Oakland, CA.
P2-11-09 Withdrawn
P2-11-10 Intra-tumor heterogeneity affects multi-gene test prognostic risk stratification
Lee AV, Lin Y, Lin H-M, Cooper KL, Normolle DP, Brufsy AM, Fastuca M, Crosson W, Oesterreich S, Davidson NE, Bhargava R, Dabbs DJ. University of Pittsburgh Cancer Institute, Pittsburgh, PA.
P2-11-11 Clinical utility of a radiosensitivity molecular signature: Identification of breast cancer patients that benefit from RT boost dose
Torres-Roca JF, Servant N, Bollet MA, Eschrich SA. Moffitt Cancer Center, Tampa, FL; Institut Curie, Paris, France.
P2-11-12 Validation of modified Magee equations for predicting the oncotype DX recurrence score: A cost-effective alternative for estimating the risk of distant recurrence in receptor positive/node negative breast cancer patients
Turner BM, Skinner K, Huston A, Schiffhauer L, Shayne M, Ling M, Zhang Z, Jackson M, Tang P, Hicks D. University of Rochester Medical Center, Rochester, NY.
P2-11-13 The 70-gene signature (70-GS) in a lymph node-negative patient series with intermediate risk 21-gene recurrence scores (RS) and known adjuvant treatment recommendations
Lo SS, Mai H, McCroskey Z, Guo R, Ersahin C, Gaynor ER, Robinson PA, Albain KS. Loyola University Chicago Stritch School of Medicine, Maywood, IL.
P2-11-14 Does the Nottingham prognostic index further refine survival within the breast cancer subtypes?
Caggiano V, Parise C. Sutter Institute for Medical Research, Sacramento, CA.
P2-11-15 Immunohistochemical assessment of Ki67 with the antibodies SP6 and MIB1 – A comparison of prognostic information and reproducibility
Ekholm M, Beglerbegovic S, Grabau D, Lövgren K, Malmström P, Werner-Hartman L, Fernö M. Ryhov County Hospital, Jönköping, Sweden; Lund University, Lund, Sweden; Växjö Central Hospital, Växjö, Sweden; Skåne University Hospital, Lund, Sweden; Skåne, Skåne University Hospital, Lund, Sweden; South Regional Cancer Center, Lund, Sweden.
P2-11-16 Prospective comparison of prognostic factors in patients starting a third line of chemotherapy for metastatic breast cancer: An ancillary study to the CirCe01 trial
Helissey C, Berger F, Guilhaume M-N, Mauborgne C, Bouleuc C, Rodrigues M, Beuzeboc P, Cottu P, Dieras V, Mignot L, Pierga J-Y, Bidard F-C. Institut Curie, Paris, France; INSERM, U900, Paris, France.
P2-11-17 L-dex ratio in detecting and diagnosing breast cancer-related lymphedema: Reliability, sensitivity, and specificity
Fu MR, Cleland CM, Guth AA, Kayal M, Haber J, Cartwright F, Kleinman R, Kang Y, Scagliola J, Axelrod D. New York University, New York, NY; NYU School of Medicine, New York, NY; NYU Cancer Center, New York, NY; Columbia University, New York, NY.
P2-11-18 Immunohistochemical expression of ubiquitin ligase CHIP (carboxyl terminus of Hsc70-interacting protein) as a significant prognostic marker in postmenopausal invasive breast cancer patients
Kurozumi S, Yamaguchi Y, Matsumoto H, Takei H, Kobayashi Y, Hayashi S-I, Yanagisawa J, Horiguchi J, Takeyoshi I, Kurosumi M. Saitama Cancer Center, Saitama, Japan; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan; Tohoku University, Miyagi, Japan; Tsukuba University, Ibaraki, Japan; Gunma University Graduate School of Medicine, Gunma, Japan.
P2-11-19 Expression of folate receptor alpha in ductal carcinoma in situ of the breast and comparison with that of invasive ductal carcinoma
Zhang Z, Wang J, Tacha D, Li P, Bremer R, Skinner K, Hicks DG, Bu H, Tang P. University of Rochester Medical Center, Rochester, NY; West China Hospital, Sichuan University, Chengdu, China; RTI Health Solutions, Research Triangle Park, NC; Biocare, Inc., Concord, CA.
P2-11-20 Evaluation of folate receptor alpha expression in breast cancer by immunohistochemistry: Analysis with three different cut-off points
Zhang Z, Wang J, Tacha D, Li P, Bremer R, Skinner K, Hicks' DG, Bu H, Tang P. University of Rochester Medical Center, Rochester, NY; West China Hospital, Sichuan University, Chengdu, China; RTI Health Solutions, Research Triangle Park, NC; Biocare, Inc., Concord, CA.
P2-11-21 Ipsilateral breast tumor recurrence in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: Validation of the MD Anderson prognostic index
Rouzier R, Bailleux M, Guinebretiere J-M, Delalande B, Lasry S, Lerebours F, Stevens D. Institut Curie, Saint-Cloud, France.
P2-11-22 The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receipt
Rutter C, Mancini B, Gross C, Aminawung J, Chagpar A, Saglam O, Hofstatter E, Abu-Khalaf M, Evans S. Yale New Haven Hospital, New Haven, CT; Yale New Haven Hospital Cancer Outcomes Public Policy and Effectiveness Research Center, New Haven, CT.
P2-11-23 MammaPrint and BluePrint in early breast cancer: Clinical implications of prognostic stratification and molecular subtyping
Yao K, Turk M, Kaul K, Wesseling J, Stork-Sloots L, de Snoo F, Cristofanilli M. NorthShore University Health System, Evanston, IL; Netherlands Cancer Institute, Amsterdam, Netherlands; Agendia NV, Amsterdam, Netherlands; Thomas Jefferson University Hospital, Philadelphia, PA.
  Epidemiology, Risk, and Prevention: Familial Breast Cancer - Genetic Testing
P2-12-01 BRCA1 and BRCA2 in multifocal cancers: Results from the POSH study
Eccles BK, Maishman T, Copson E, Stanton L, Eccles DM. University of Southampton Clinical Trials Unit and Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton and University Hospital Southampton Foundation Trust, Southampton, United Kingdom.
P2-12-02 Characteristics of the BRCA mutation profile of a population of patients with triple negative breast cancer
Luporsi E, Bronner M, Lesur A, Saint-Dizier D, Sokolowska J, Mansuy L, Jonveaux P. ICL Alexis Vautrin, Vandoeuvre les nancy, France; Laboratoire de Génétique - CHU de Brabois, Vandoeuvre les nancy, France.
P2-12-03 BRCA1/2 testing in an urban population of black women (BW)
Lynce F, Stein JE, Demarco T, Isaacs C, Smith KL. MedStar Washington Hospital Center, Washington, DC; George Washington University, Washington, DC; Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC; MedStar Georgetown University Hospital, Washington, DC; The Johns Hopkins Sidney Kimmel Cancer Center.
P2-12-04 Evaluation of BRCA 1/2 mutation-carrier probability models, BRCAPRO and myriad II, in the Japanese population
Ito M, Yasuda Y, Furuta A, Ohuchi N. Ishinomaki Red Cross Hospital, Ishinomaki, Miyagi, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
P2-12-05 Exploring the experience of relatives with whom genetic test results are communicated
Daly M, Montgomery S, Bingler R, Barsevik A, Ruth K. Fox Chase Cancer Center, Philadelphia, PA; Jefferson University, Philadelphia, PA.
P2-12-06 Implementing a comprehensive genetic risk assessment and testing service at an outpatient breast imaging center
Wilson K, Sweeney L. University of Texas Health Science Center- Houston, Houston, TX; Memorial Hermann Breast Care Center, Houston, TX.
P2-12-07 The correlation between Myriad Genetic Laboratories, Inc. mutation prevalence table and clinicopathological characteristics of breast cancer patients in Okinawa
Arakaki M, Kamada Y, Uehara K, Tamaki K, Tamaki N. Nahanishi Clinic Okinawa, Naha, Okinawa, Japan.
P2-12-08 Genetic testing for breast cancer risk estimation: A cost-effectiveness analysis
Folse HJ, Dinh TA, Allman R. Archimedes, Inc., San Francisco, CA; Genetic Technologies, Ltd., Fitzroy, Victoria, Australia.
P2-12-09 Developing clinical sequencing assays at Einstein-Montefiore
Delio M, Patel K, Maslov A, Golden A, Greally J, Morrow B, Vijg J, Montagna C. Albert Einstein College of Medecine, Bronx, NY.
  Epidemiology, Risk, and Prevention: Familial Breast Cancer - Molecular Genetics
P2-13-01 The Brazilian founder TP53 p.R337H mutation is uncommon in Portuguese women diagnosed with breast cancer
Giacomazzi J, Correia RL, Palmero EI, Gaspar JF, Almeida M, Portela C, Camey SA, Reis RM, Ashton-Prolla P. Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal.
P2-13-02 Clinically derived genomic signatures encompass latent biology: A case study in breast cancer
Knowlton NS, Arend M, Black M, Miller LD, Print CG. University of Auckland, Auckland, New Zealand; Auckland Hospital, Auckland, New Zealand; University of Otago, Dunedin, New Zealand; Wake Forest University School of Medicine, Winston-Salem, NC.
  Epidemiology, Risk, and Prevention: Risk Factors and Modeling
P2-14-01 Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence
Vreeland TJ, John BS, Trappey AF, Schneble EJ, Hale DF, Clifton GT, Shumway NM, Perez SA, Papamichail M, Ponniah S, Peoples GE, Mittendorf EA. San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece.
P2-14-02 A new evolving breast cancer risk evaluation model able to drive patients to personalized screening/prevention programs
Gauthier E, Fagherazzi G, Ragusa S, Dunant A, Clavel-Chapelon F, Delaloge S. Statlife, Villejuif, France; Inserm Equipe E3N, Villejuif, France; Institut Gustave Roussy, Villejuif, France.
P2-14-03 Development and evaluation of a prediction model based on routine clinicopathological variables for predicting underestimated invasive breast cancer in women with ductal carcinoma in situ at stereotactic large core needle biopsy
Diepstraten SCE, van de Ven SMWY, Pijnappel RM, Peeters PHM, van den Bosch MAAJ, Verkooijen HM, Elias SG. University Medical Center Utrecht, Utrecht, Netherlands; Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands; Stanford University Medical Center, Stanford, CA.
P2-14-04 Effect of age at the time of diagnosis on overall and cancer-specific mortality in breast cancer: Analysis of SEER, 1990-2008
Bao J, Yu K-D, Jiang Y-Z, Di G-H. Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
P2-14-05 Sporadic breast cancer risk assessment in women without family history and biopsy using the OncoVue® polyfactorial model
Jupe ER, Pugh TW, Knowlton NS, DeFreese DC. InterGenetics Incorporated, Oklahoma City, OK; NSK Statistical Solutions, LLC, Choctaw, OK.
P2-14-06 Characterization of risk factors in breast cancer young adult patients
Encinas G, Diz MDPE, Lyra EC, Katayama MLH, Pasini FS, Brentani MM, Chammas R, Góes JCGS, Folgueira MAAK. Instituto do Câncer do Estado de São Paulo (ICESP); Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, Brazil.
P2-14-07 Impact of reproductive risk factor on breast cancer survival according to menopausal status: A register based study from Korea
Kim SH, Kim WW, Lee JY, Lee JS, Oh MK. Haeundae Paik Hospital, Pusan, Republic of Korea; University of Inje, Pusan, Republic of Korea.
P2-14-08 Plasma pro-enkephalin and pro-neurotensin for the risk prediction of incident breast cancer in healthy women
Melander O, Orho-Melander M, Almgren P, Manjer J, Hedblad B, Engstr[ouml]m G, Struck J, Nilsson P, Bergmann A, Belting M. Lund University, Malmö, Sweden; Sphingotec GmbH, Hennigsdorf, Germany; Skane University Hospital, Malmö, Sweden.
  Treatment: Adjuvant Therapy - Targeted
P2-15-01 Impact of adjuvant trastuzumab (AT) on survival in metastatic (M1) her2 positive breast cancer
Lohrisch C, Speers C, Francl M, Tyldesley S. BC Cancer Agency, VAncouver Centre, Vancouver, BC, Canada.
P2-15-02 Trastuzumab treatment of early breast cancer: Long-term results from a prospective observation study, including a large cohort of elderly patients
Dall P, Lenzen G, Göhler T, Feisel-Schwickeradi G, Koch T, Heilmann V, Schindler C, Wilke J, Tesch H, Selbach J, Eggert J, Hinke A. Städtisches Klinikum, Frauenklinik, Lüneburg, Germany; Practice, Osnabrück, Germany; Practice, Dresden, Germany; Klinikum Kassel, Kassel, Germany; Klinikum Nürnberg Nord, Frauenklinik, Nürnberg, Germany; Practice, Günzburg, Germany; Practice, Leipzig, Germany; Practice, Fürth, Germany; Onkologie Bethanien, Frankfurt, Germany; Practice, Duisburg, Germany; Practice, Moers, Germany; WiSP Research Institute, Langenfeld, Germany.
P2-15-03 Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874g
Krop IE, Suter TM, Dirix L, Romieu G, Zamagni C, Citron ML, Campone M, Dang CT, Xu N, Smitt M, Gianni L. Dana-Farber Cancer Institute, Boston, MA; Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland; Sint-Augustinus Hospital, Antwerp, Belgium; ICM Val d'Aurelle, Montpellier, France; Policlinico S.Orsola-Malpighi Hospital, Bologna, Italy; Hofstra North Shore-LIJ School of Medicine, Hyde Park, NY; Institut de Cancérologie de l'Ouest/René Gauducheau, Nantes Saint Herblain, France; Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech, Inc., South San Francisco, CA; San Raffaele Hospital, Milan, Italy.
P2-15-04 Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: The HERA trial experience
Metzger Filho O, Procter M, de Azambuja E, Krieguer M, Gelber RD, Piccart M. Dana-Farber Cancer Institute; Frontier Science; Institut Jules Bordet.
  Treatment: Advanced Therapy - Targeted
P2-16-01 A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC)
Dieras V, Yardley D, Romieu G, Valero V, Isakoff S, Koeppen H, Thurm H, Teng M, Campone M, Mocci S. Institut Curie, Paris, France; SCRI/Tennessee Oncology, PLLC, Nashville, TN; ICM Institut du Cancer Montpellier, Montpellier, France; UT MD Anderson Cancer Center, Houston; Massachusetts General Hospital, Boston; Genentech, Inc., South San Francisco; Institut de Cancérologie de l'ouest, Saint Herbalin-Nantes Cedex, France.
P2-16-02 Bevacizumab, etoposide, and cisplatin (BEEP) is highly effective in brain metastases of HER2 positive breast cancer progressing from whole brain radiotherapy – Subgroup analysis of a multi-center phase II study
Lu Y-S, Chen W-W, Lin C-H, Yeh D-C, Tseng L-M, Rau K-M, Chen B-B, Chao T-C, Wu P-F, Huang S-M, Shih TT-F, Huang C-S, Cheng A-L. National Taiwan University Hospital, Taipei, Taiwan; Taichung Veterans General Hospital, Taichung, Taiwan; Taipei Veterans General Hospital, Taipei, Taiwan; Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
P2-16-03 Mature results on metastatic breast cancer patients with prolonged (≥1 year) exposure to first-line bevacizumab combined with paclitaxel from a large observation study
Schmidt M, Schneeweiss A, Förster F, Geberth M, Schumacher C, Hollburg W, Söling U, Aktas B, Kümmel S. University Hospital, Mainz, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University of Applied Sciences Zwickau, Chemnitz, Germany; SPGO-Mannheim, Mannheim, Germany; St. Elisabeth-Hospital, Köln, Germany; HOPA (Hämatologisch-Onkologische Praxis Altona) im Struenseehaus, Hamburg, Germany; Practice, Kassel, Germany; University Clinic, Essen, Germany; Kliniken Essen-Mitte, Essen, Germany.
P2-16-04 A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer
Baselga J, Morales S, Awada A, Blum J, Tan A, Ewertz M, Cortes J, Moy B, Ruddy K, Haddad T, Ciruelos E, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Prathiraja K, Gause C, Mauro D, Rugo H. Memorial Sloan Kettering, New York, NY; H. de Lleida Arnau de Vilanova, Lerida, Spain; Institut Jules Bordet, Brussels, Belgium; Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX; The Cancer Institute of New Jersey, New Brunswick, NJ; Odense Universitets Hospital, Odense, Denmark; Vall d'Hebron University Hospital, Barcelona, Spain; Massachusetts General Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA; University of Minnesota Masonic Clinical Cancer Center, Minneapolis, MN; Hospital 12 de Octubre, Madrid, Spain; Clinique Sainte Elisabeth, Namur, Belgium; Merck Research Laboratories, North Wales, PA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
P2-16-05 Efficacy of ABT-888 (veliparib) in patients with BRCA-associated breast cancer
Somlo G, Frankel P, Luu T, Ma C, Arun B, Garcia A, Cigler T, Fleming G, Harvey H, Sparano J, Nanda R, Chew H, Moynihan T, Vahdat L, Goetz M, Hurria A, Mortimer J, Gandara D, Chen A, Weitzel J. City of Hope Cancer Center, Duarte, CA; Washington University School of Medicine, St. Louis, MO; The University of Texas MD Anderson Cancer Center, Houston, TX; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Weill Cornell Medical College, New York, NY; Alliance for Clinical Trials in Oncology, Chicago, IL; Milton S. Hershey Medical Center, Hershey, PA; Montefiore Medical Center, Bronx, NY; University of Chicago, Chicago, IL; University of California, Davis Cancer Center, Sacramento, CA; Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD.
P2-16-06 Influence of trastuzumab pre-exposure in non metastatic disease to first line metastatic treatment efficacy including trastuzumab: The University Cancer Center - University Pierre & Marie Curie (IUC-UPMC) experience
Gligorov J, Vignot S, Richard S, Lotz J-P, Khayat D, Spano J-P. Institut Universitaire de Cancérologie, Université Pierre et Marie Curie, Sorbonne University, Paris, France.
P2-16-07 Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
Iyengar NM, Datko FM, D'Andrea G, Dickler MN, Goldfarb S, Theodoulou M, Lake D, Fornier MN, Modi S, Fasano J, Comen E, Gajria D, Moynahan ME, Traina TA, Patil S, Liu J, Jochelson M, Norton L, Hudis CA, Dang CT. Memorial Sloan-Kettering Cancer Center, New York, NY.
P2-16-08 LORHA: Efficacy and safety of 1st-line trastuzumab based treatment, administered for at least 3 years, in patients with HER2-positive metastatic or locally advanced breast cancer – Final results
Ferrero J-M, Levy C, Spano J-P, Beuzeboc P, Coeffic D, Arnould L, Lortholary A, André F, Mayer F. Centre Antoine-Lacassagne, Nice, France; Centre François Baclesse, Caen, France; Hôpital Pitié-Salpêtrière, Paris, France; Institut Curie, Paris, France; Clinique Hartmann, Neuilly sur Seine; Centre Georges François Leclerc, Dijon, France; Centre Catherine de Sienne, Nantes, France; Institut Gustave Roussy, Villejuif, France.
P2-16-09 Retrospective analysis of long-term survivors with HER2+ metastatic breast cancer (MBC) treated with trastuzumab in a community setting
Jones S, Tseng W-Y, Saravanan S, Santos E, Dhanda R, Rembert DS, Yap MA, Lalla D, Brammer M. McKesson Specialty Health and The US Oncology Network, The Woodlands, TX; Genentech, Inc., Medical Affairs, South San Francisco, CA; Former Employee of Genentech, Inc., Medical Affairs, South San Francisco, CA.
P2-16-10 Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
Perez EA, López-Vega JM, Del Mastro L, Petit T, Zamagni C, Freudensprung U, Bastière-Truchot L, Walker R, Andersson M. Mayo Clinic, Jacksonville, FL; Hospital Universitario Marqués de Valdecilla, Santander, Spain; IRCCS San Martino – IST, Genoa, Italy; Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France; Policlinico S.Orsola-Malpighi Hospital, Bologna, Italy; Stamford Consultants AG on Behalf of Roche, Basel, Switzerland; Roche, Basel, Switzerland; Rigshospitalet, Copenhagen, Denmark.
P2-16-11 Impact of adjuvant trastuzumab (T) with chemotherapy on breast cancer specific and cardiac outcomes in older women with small, node-negative HER2-positive breast cancer
Cadoo KA, Morris PG, Patil S, Norton L, Hudis CA, McArthur HL. Memorial Sloan Kettering Cancer Center, New York.
P2-16-12 An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
Cadoo KA, Morris PG, Lake DE, D'Andrea GM, Dickler MN, Gilewski TA, Dang CT, McArthur HL, Bromberg JF, Goldfarb SB, Modi S, Robson ME, Seidman AD, Sklarin NT, Norton L, Hudis CA, Fornier MN. Memorial Sloan Kettering Cancer Center, New York, NY.
P2-16-13 Phase I dose escalation clinical trial of the PI3K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC)
Dees EC, Marcom PK, Snavely A, Noe J, Anders CK, Blackwell K, Kimmick G, Reeder-Hayes K, Rosenstein D, Perou CM, Carey LA. UNC- Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Duke University Medical Center, Durham, NC.
P2-16-14 Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study
Juric D, Gonzalez-Angulo AM, Burris HA, Schuler M, Schellens J, Berlin J, Gupta A, Seggewiss-Bernhardt R, Adamo B, Gil-Martin M, Bootle D, Boehm M, De Buck S, Demanse D, Quadt C, Baselga J. Massachusetts General Hospital Cancer Center, Boston, MA; M.D. Anderson Cancer Center, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University Hospital Essen, Essen, Germany; The Netherlands Cancer Institute, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Oxford University Hospitals NHS Trust, Oxford, United Kingdom; CCC MF, University Hospital Würzburg, Würzburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Memorial Sloan-Kettering Cancer Center, New York, NY.
P2-16-15 Withdrawn
P2-16-16 Incidence and risk of treatment-related mortality with everolimus in cancer patients
Macrae E, Abdel-Rasoul M, Lustberg M, Paskell M, Shapiro CL, Wesolowski R. The Ohio State University, Columbus, OH.
P2-16-17 Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer
Burris H, Gnant M, Hortobagyi G, Hart L, Yardley DA, Eakle J, Provencher L, Brechenmacher T, Saletan S, Taran T, Rugo H. Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF.
P2-16-18 Withdrawn
P2-16-19 Fulvestrant with or without selumetinib (Sel, AZD6244), a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor (AI): A multicenter randomized placebo-controlled double-blind phase II trial, SAKK21/08
Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Biaggi Rudolf C, Rondeau S, Neven P. University Hospital CHUV, Lausanne, Switzerland; Lucerner Kantonsspital, Luzerne, Switzerland; Kantonsspital Aarau, Switzerland; Breast Center, Kantonsspital, St Gallen, Switzerland; Breast Center, Universitätsspital, Basel, Switzerland; Kantonsspital, Winterthur, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital Gasthuisberg, Leuven, Belgium; Morges Hospital, Morges, Switzerland.
P2-16-20 Biomarkers to predict response to the CDK 4/6 inhibitor, palbociclib (PD 0332991) in a single-agent phase II trial in advanced breast cancer
Clark AS, Lal P, Tan KS, Heitjan DF, Randolph S, Feldman M, Zhang P, Gallagher M, Domchek S, Gogineni K, Keefe S, Fox KR, O'Dwyer P, DeMichele A. Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA; Pfizer, New York, NY.
P2-16-21 A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer
Nanda R, Chennamaneni P, Gibson J, Koetter K, Libao B, Skor M, Maranville J, Hoffman P, Obeid E, DiRienzo A, Fleming G, Conzen S. University of Chicago, Chicago, IL.
P2-16-22 A dose-finding phase lb study of BEZ235 in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer
Gil-Martin M, Fumoleau P, Isambert N, Urruticoechea A, Beck JT, Csonka D, di Tomaso E, Gaur A, Roiffe K, Urban P, Vincent G, Campone M. Institut Català d'Oncologia, Barcelona, Spain; Centre Georges François Leclerc, Dijon, France; Highlands Oncology Group, Fayetteville, AR; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for BioMedical Research, Cambridge, MA; Novartis Healthcare Pvt. Ltd, Hyderabad, India; Novartis Oncology, Paris, France; Institut de Cancérologie de l'Ouest//Centre René Gauducheau, Saint Herblain-Nantes, France.
P2-16-23 The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)
Awada A, Spector N, El-Hariry I, Rodriguez AA, Erban JK, Cortes J, Gomez H, Kong A, Hickish T, Fein L, Vahdat L, MacPherson I, Canon J-L, Mansoor S, Giovanne A, McAdam K, Vukovic VM, Yalcin I, Bradley R, Proia D, Mano MS, Perez EA, Cameron DA. Jules Bordet Institute, Brussels, Belgium; Duke University Medical Center, Durham; Synta Pharmaceuticals Inc, Lexington; The Methodist Hospital Research Institute, Houston; Tufts Medical Center, Boston; Vall d'Hebron University Hospital, Barcelona; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Churchill Hospital, Oxford University Hospitals NHS Trust and University of Oxford, Oxford, United Kingdom; The Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom; Centro Oncológico de Rosario, Rosario Santa Fe, Argentina; Weill Cornell Medical College, New York; The Beatson Institute for Cancer Research, Glasgow, United Kingdom; Grand Hôpital de Charleroi, Charleroi, Belgium; Georgia Cancer Specialists, Atlanta; Hospital Central de la Fuerza Aérea del Perú, Lima, Peru; Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, United Kingdom; Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil; Mayo Clinic, Jacksonville; Edinburgh University, Edinburgh, United Kingdom.
P2-16-24 Folate targeted SMDC's: A possible new treatment alternative for folate receptor expressing TNBC patients
Leamon CP, Reddy JA, Nelson M, Bloomfield A, Dorton R, Vetzel M. Endocyte Inc., West Lafayette, IN.
  Treatment: Signal Transduction Inhibitors
P2-17-01 The PI3K inhibitor GDC-0032 is selectively potent against PIK3CA mutant breast cancer cell lines and tumors
Wallin JJ, Edgar KA, Guan J, Sampath D, Nannini M, Belvin M, Friedman LS. Genentech, Inc., South San Francisco, CA.
P2-17-02 Withdrawn
  Treatment: Surgery
P2-18-01 Withdrawn
P2-18-02 Factors associated with contralateral prophylactic mastectomy in young women with breast cancer
Rosenberg SM, Sepucha K, Ruddy KJ, Tamimi RM, Gelber S, Meyer ME, Schapira L, Come SE, Borges VF, Winer EP, Partridge AH. Harvard School of Public Health, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; University of Colorado-Denver, Denver, CO.
P2-18-03 Feasibility of sentinel node biopsy following neoadjuvant chemotherapy in cytology-proven node positive breast cancer before chemotherapy
Enokido K, Watanabe C, Nakamura S, Ogiya A, Osako T, Akiyama F, Horio A, Iwata H, Ohno S, Kojima Y, Tsugawa K, Motomura K, Hayashi N, Yamauchi H, Sato N. Showa University Hospital, Tokyo, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; National Kyushu Cancer Center, Japan; St. Marianna University School of Medicine, Kawasaki; Osaka Medical Center for Cancer and Cardiovascular Diseases; St Luke's International Hospital; Niigata Cancer Center Hospital.
P2-18-04 No further axillary dissection in sentinel lymph node-negative breast cancer after neoadjuvant chemotherapy in patients with initial cytologically-proven axillary node metastasis
Lee HC, Lee JH, Kim MK, Kil WH, Kim J, Lee JE, Kim SW, Nam SJ, Kim SM, Bae SY, Lee SK, Kim J. Samsung Medical Center, Seoul, Korea.
P2-18-05 Axillary nodal burden in patients with a positive pre-operative ultrasound guided fine needle aspiration cytology
Boland MR, Prichard RS, Daskalova I, Lowery AJ, Maguire A, Evoy D, Geraghty J, Rothwell J, Quinn CM, O'Doherty A, McDermott EW. St Vincent's Healthcare Group, Dublin, Ireland.
P2-18-06 Preservation or division of the intercostobrachial nerve in axillary dissection for breast cancer: Meta-analysis of randomised controlled trials
Warrier SK, Hwang S, Koh C, Shepherd H, Mak C, Carmalt H, Solomon M. Royal Prince Alfred Hospital, Sydney, NSW, Australia; Prince of Wales Hospital, Sydney, NSW, Australia; University of Sydney, Camperdown, Sydney, NSW, Australia; University of New South Wales, Randwick, Sydney, NSW, Australia; Surgical Outcomes Research Centre, Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia.
P2-18-07 Nipple sparing mastectomy-infectious complication risk. A preliminary assessment of the American Society of Breast Surgeons nipple sparing mastectomy registry
Mitchell SD, Feldman SM, Beitsch PD, Willey SC, Manasseh DME, Unzeitig GW. White Plains Hospital, White Plains, NY; Columbia University College of Physicians & Surgeons, New York, NY; Dallas Breast Center, Dallas, TX; Georgetown, Washington, DC; Maimonides, Brooklyn, NY; Laredo Breast Care, Laredo, TX.
P2-18-08 Nipple-sparing mastectomy for patients with multifocal breast cancer
Sakurai T, Sasaki E, Suzuma T, Yoshumura G, Umemura T, Sakurai T. Wakayama Medical University Kihoku Hospital, Ito, Wakayama, Japan; Kushimoto Arida Hospital, Wakayama, Japan; Kishiwada Shimin Hospital, Osaka, Japan; Kiwa Breast Center, Wakayama, Japan; Sakurai Breast Clinic, Wakayama, Japan.
P2-18-09 TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer
King TA, Lyman JP, Gonen M, Voci A, Boafo C, Hwang ES, Rugo HS, Alvarado M, Liu M, Boughey JC, Jacobs LK, Krontiras H, McGuire K, Storniolo AM, Nanda R, Golshan M, Isaacs C, Bijelic L, Meszoely IM, Van Poznak C, Babiera G, Norton L, Morrow M, Winer EP, Wolff AC, Hudis CA. Memorial Sloan-Kettering Cancer Center, New York, NY; Duke University Medical Center, Durham, NC; University of California San Francisco, San Francisco, CA; Mayo Clinic, Rochester, MN; John Hopkins Medical Institution, Baltimore, MD; University of Alabama At Birmingham, Birmingham, AL; University of Pittsburgh Medical Center, Pittsburgh, PA; Indiana University Simon Cancer Center, Indianapolis, IN; University of Chicago, Chicago, IL; Dana Farber Cancer Institute, Boston, MA; Georgetown University, Washington, DC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; Translational Breast Cancer Research Consortium.
P2-18-10 High risk of late in-breast tumour recurrence after BRCA1/2-associated breast cancer
Nilsson M, Hartman L, Kristoffersson U, Olsson H, Borg Å, Henriksson K, Lanke E, Loman N. Lund University, Sweden; Regional Cancer Centre, Lund, Sweden.
P2-18-11 A multi-center prospective study of image-guided radiofrequency ablation for small breast carcinomas
Kinoshita T, Fujisawa T, Yamamoto N, Takabatake D, Takahashi M, Wada N, Asaga S, Iwamoto E. National Cancer Center Hospital, Tokyo, Japan; Gnuma Prefectural Cancer Center, Ohta, Japan; Chiba Cancer Center, Chiba, Japan; Shikoku Cancer Center, Matsuyama, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Cancer Center Hospital East, Kashiwa, Japan.
P2-18-12 Surgical management of breast cancer: Breast conserving surgery or mastectomy in the 2010 SEER registries by hormone receptor and HER2 status
Schroeder MC, Sugg SL, Brooks JM, Thomas A. University of Iowa, Iowa City, IA.
P2-18-13 Withdrawn
P2-18-14 MarginProbe® - Final results of the German post-market study in breast conserving surgery of ductal carcinoma in situ
Thill M, Dittmer C, Blohmer J-U, Baumann K, Friedrichs K. Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Breast Cancer Centre, Hospital Essen Mitte, Essen, Germany; University Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Breast Cancer Centre, Jerusalem Hospital, Hamburg, Germany; Breast Cancer Centre, Sankt-Gertrauden Hospital, Berlin, Germany.
P2-18-15 Primary site surgery for metastatic breast cancer: Patterns of care and cause-specific survival
Russell TA, Axelrod D, Rescigno J. David Geffen School of Medicine at UCLA, Los Angeles, CA; NYU Langone Medical Center, New York, NY; Continuum Cancer Centers of New York - Beth Israel Medical Center, New York, NY.
P2-18-16 Patients' impression of the expected appearance of breasts in 2013
Komenaka IK, Hsu C-H, Bouton ME, Olson L, Pond E, Nodora J, Martinez ME, Nesset EM, Maffi TR. Maricopa Medical Center, Phoenix, AZ; University of Arizona, Tuscon, AZ; University of California - San Diego, San Diego, CA.
P2-18-17 Breast cancer surgery for the elderly - Are we meeting a growing need?
Olsen SB, Davies M, Cameron D, Cook L, Dunn J. Royal Devon and Exeter Hospital Foundation NHS Trust, Exeter, Devon, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom.
P2-18-18 Improving training in breast surgical oncology: The development and preliminary validation of a simulator for wide local excision
Leff DR, Petrou G, Mavroveli S, Berishand M, Cocker D, Al-Mufti R, Darzi A, Hanna G, Hadjiminas D. Imperial College London, London, United Kingdom; Imperial Healthcare NHS Trust, London, United Kingdom.
  Treatment: Reconstruction
P2-19-01 Impact of breast reconstruction approach on patient-reported satisfaction with cosmetic outcomes after mastectomy with and without radiotherapy
Jagsi R, Li Y, Morrow M, Janz N, Alderman A, Graff J, Hamilton A, Katz SJ, Hawley S. University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Swan Center for Plastic Surgery; UMDNJ; University of Southern California.
P2-19-02 Do older women benefit from post-mastectomy breast reconstruction?
Sisco M, Johnson DB, Wang CE, Yao KA. NorthShore University HealthSystem, Evanston, IL.
P2-19-03 The effect of adjuvant radiotherapy on revision surgery rates in women having mastectomy and immediate latissimus dorsi flap with implant reconstruction of the breast
Keogh KM, Twelves DJ, Workman R, Daulatzai N, Hock CY. Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom.
P2-19-04 Latissimus dorsi muscle onlay patch alternative to acellular dermal matrix is useful for implant-based breast reconstruction
Lee J, Bae Y, Lee S. Pusan National University Hospital, Busan, Republic of Korea.
P2-19-05 Oncoplastic breast conserving surgery with perforator flap in breast cancer patients
Park HY, Kang JG, Choi HH, Hwang SO, Kim WW, Jung JH, Lee YH, Yang JD, Lee SJ. Kyungpook National University Medical Center, Daegu, Gyeongsangbuk-Do, Republic of Korea; Hyosung Hospital, Daegu, Gyeongsangbuk-Do, Republic of Korea.
P2-19-06 Breast conserving surgery using volume replacement with oxidized regenerated cellulose: A cosmetic outcome analysis
Tanaka S, Iwamoto M, Kimura K, Takahashi Y, Fujioka H, Sato N, Terasawa R, Uchiyama K. Osaka Medical College Hospital, Takatsuki, Osaka, Japan.
P2-19-07 Current trends of breast reconstruction after mastectomy for breast cancer patients in China
Chen Y, Chen J, Chen J, Yang B, Li L, Huang X, Shao Z, Shen Z, Wu J. Shanghai Cancer Center, Fudan University, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China.
P2-19-08 Phase III development of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) module for women undergoing breast reconstruction: The EORTC QLQ-BRR26
Winters ZE, Balta V, Thomson HJ, Llewellyn-Bennett R, Oberguggenberger A, Sinove Y, Nava M, Bruno N, Sandelin K, Unukovych D, Blondeel P, Brandberg Y, Johansson H. University of Bristol, School of Clinical Sciences, Bristol, South West, United Kingdom; Medical University of Innsbruck, Innsbruck, Austria; University Hospital of Ghent, Ghent, Belgium; Instituto Tumori Milano, Milan, Italy; Karolinska Institute, Stockholm, Sweden.
P2-19-09 A multi-centre prospective phase - 2 surgical study evaluating health related quality of life after immediate latissimus dorsi (LD) breast reconstruction: Duration of effects over 2 years
Winters ZE, Balta V, Freeman J, Llewellyn-Bennett R, Galea M, Mcmanus P, Nicholson S, Rayter Z, Weiler-Mithoff E, Greenwood R. University of Bristol, School of Clinical Sciences, Bristol, South West, United Kingdom; NIHR Research Design Services, Bristol, South West, United Kingdom; Western General NHS Foundation Trust, Swindon, South West, United Kingdom; Hull and East Yorkshire NHS Trust, York, Yorkshire, United Kingdom; Newcastle University NHS Foundation Trust, Newcastle, United Kingdom; Canniesburn Western General NHS Trust, Glasgow, Scotland, United Kingdom.
P2-19-10 Quality of life following mastectomy and breast reconstruction (QUEST): Learning from two feasibility randomized controlled clinical trials
Winters ZE, Mills J, Emson M, Griffin C, Hopwood P, Bidad N, Turton P, Horne R, Bliss J. University of Bristol, School of Clinical Sciences, Breast Cancer Clinical Outcomes and PROMS Research Group, Bristol, South West, United Kingdom; Institute of Cancer Research, Cancer Research UK, Clinical Trials Unit, London, United Kingdom; University College London, Centre for Behavioural Medicine, London, United Kingdom; Leeds NHS Foundation Trust, Leeds, United Kingdom.
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy